Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / OMER - Omeros: No Partner - No Money


OMER - Omeros: No Partner - No Money

Omeros Corporation (OMER) is commercial stage pharmaceutical company with one marketed drug - Omidria, one late-stage, and several early-stage drug candidates.

Omidria is used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

Omidria is phenylephrine and ketorolac intraocular solution (1%/0.3%), and it was approved by FDA in 2014.

Actually, it is a combination of 2 previously available medicines: mydriatic phenylephrine and nonsteroidal anti-inflammatory drug ketorolac.

Despite the promising projections and Medicare coverage, the company still has not achieved a serious

Read more ...

Stock Information

Company Name: Omeros Corporation
Stock Symbol: OMER
Market: NASDAQ
Website: omeros.com

Menu

OMER OMER Quote OMER Short OMER News OMER Articles OMER Message Board
Get OMER Alerts

News, Short Squeeze, Breakout and More Instantly...